Postoperative nomogram to predict cancer-specific survival after radical nephroureterectomy in patients with localised and/or locally advanced upper tract urothelial carcinoma without metastasis

BJU International

Volumn 114, Issue 5, 2014, Pages 733-740

  Seisen, Thomas ^a   Colin, Pierre ^b,c   Hupertan, Vincent ^d   Yates, David R ^a   Xylinas, Evanguelos ^e   Nison, Laurent ^f   Cussenot, Olivier ^a   Neuzillet, Yann ^g   Bensalah, Karim ^h   Novara, Giacomo ⁱ   Montorsi, Francesco ^j   Zigeuner, Richard ^k   Remzi, Mesut ^l   Shariat, Shahrokh F ^m   Rouprêt, Morgan ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b Clinique Parc Monceau   (France)

^c Seclin General Hospital   (France)

^d BICHAT HOSPITAL   (France)

^e Institut Cochin   (France)

^f UNIV LILLE   (France)

^g FOCH HOSPITAL   (France)

^h PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

ⁱ OSPEDALI RIUNITI   (Italy)

^j VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^k MEDICAL UNIVERSITY OF GRAZ   (Austria)

^l Medical University of Landeskrankenhaus Weinviertel Korneuburg   (Austria)

^m MEDICAL UNIVERSITY OF VIENNA   (Austria)

more..

Author keywords

chemotherapy; nephroureterectomy; nomogram; renal pelvis; ureter; urothelial carcinoma

Indexed keywords

ACCURACY; ADVANCED CANCER; ADVANCED UPPER TRACT UROTHELIAL CARCINOMA; AGE; AGED; ANALYSIS; ARTICLE; BOOTSTRAPPING; CALIBRATION; CANCER GRADING; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; CANCER STAGING; CARCINOMA IN SITU; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTROLLED STUDY; DECISION CURVE ANALYSIS; FEMALE; FOLLOW UP; HUMAN; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHROURETERECTOMY; NOMOGRAM; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PROBABILITY; PROCESS OPTIMIZATION; RADICAL NEPHROURETERECTOMY; RETROSPECTIVE STUDY; SURGICAL APPROACH; SURVIVAL TIME; TRANSITIONAL CELL CARCINOMA; VALIDATION PROCESS; MIDDLE AGED; MORTALITY; NEPHRECTOMY; PATHOLOGY; PROCEDURES; RANDOMIZATION; SURVIVAL; URETER; UROLOGIC NEOPLASMS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; NEPHRECTOMY; NOMOGRAMS; RANDOM ALLOCATION; SURVIVAL ANALYSIS; URETER; UROLOGIC NEOPLASMS;

EID: 84912561931     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12631     Document Type: Article

References (25)

1. Rouprêt M, Babjuk M, Compérat E, et al. European guidelines on upper urinary tract urothelial carcinomas: 2013 update. Eur Urol 2013; 63: 1059-1071
2. Catto JW, Hartmann A, Stoehr R, et al. Multifocal urothelial cancers with the mutator phenotype are of monoclonal origin and require panurothelial treatment for tumor clearance. J Urol 2006; 175: 2323-2330
3. Catto JW, Yates DR, Rehman I, et al. Behavior of urothelial carcinoma with respect to anatomical location. J Urol 2007; 177: 1715-1720
4. Green DA, Rink M, Xylinas E, et al. Urothelial carcinoma of the bladder and the upper tract: disparate twins. J Urol 2013; 189: 1214-1221
5. Cha EK, Shariat SF, Kormaksson M, et al. Predicting clinical outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. Eur Urol 2012; 61: 818-825
6. Rouprêt M, Hupertan V, Seisen T, et al. Prediction of cancer specific survival after radical nephroureterectomy for upper tract urothelial carcinoma: development of an optimized postoperative nomogram using decision curve analysis. J Urol 2013; 189: 1662-1669
7. Yates DR, Hupertan V, Colin P, et al. Cancer-specific survival after radical nephroureterectomy for upper urinary tract urothelial carcinoma: proposal and multiinstitutional validation of a post-operative nomogram. Br J Cancer 2012; 106: 1083-1088
8. Vassilakopoulou M, de la Motte Rouge T, Colin P, et al. Outcomes after adjuvant chemotherapy in the treatment of high-risk urothelial carcinoma of the upper urinary tract (UUT-UC): results from a large multicenter collaborative study. Cancer 2011; 117: 5500-5508
9. Hellenthal NJ, Shariat SF, Margulis V, et al. Adjuvant chemotherapy for high risk upper tract urothelial carcinoma: results from the Upper Tract Urothelial Carcinoma Collaboration. J Urol 2009; 182: 900-906
10. Birtle AJ, Lewis R, Johnson M, Hall E, POUT Trial Management Group (TMG). Time to define an international standard of postoperative care for resected upper urinary tract transitional cell carcinoma (TCC)-opening of the peri-operative chemotherapy versus surveillance in upper tract urothelial cancer (POUT) Trial. BJU Int 2012; 110: 919-921
11. Lughezzani G, Burger M, Margulis V, et al. Prognostic factors in upper urinary tract urothelial carcinomas: a comprehensive review of the current literature. Eur Urol 2012; 62: 100-114
12. Ariane MM, Colin P, Ouzzane A, et al. Assessment of oncologic control obtained after open versus laparoscopic nephroureterectomy for upper urinary tract urothelial carcinomas (UUT-UCs): results from a large French multicenter collaborative study. Ann Surg Oncol 2012; 19: 301-308
13. Harrell FE Jr, Lee KL, Mark DB,. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996; 15: 361-387
14. Epstein JI, Amin MB, Reuter VR, Mostofi FK,. The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-1448
15. Remzi M, Haitel A, Margulis V, et al. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int 2009; 103: 307-311
16. Kikuchi E, Margulis V, Karakiewicz PI, et al. Lymphovascular invasion predicts clinical outcomes in patients with node-negative upper tract urothelial carcinoma. J Clin Oncol 2009; 27: 612-618
17. Harrell FE Jr,. Design: Design Package. R package version 2.3-0. 2009. Available at: http://CRAN.Rproject.org/package=Design. Accessed 2009
18. Vickers AJ, Elkin EB,. Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making 2006; 26: 565-574
19. Vickers AJ, Cronin AM, Elkin EB, Gonen M,. Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers. BMC Med Inform Decis Mak 2008; 8: 53
20. Drouin SJ, Yates DR, Hupertan V, Cussenot O, Rouprêt M,. A systematic review of the tools available for predicting survival and managing patients with urothelial carcinomas of the bladder and of the upper tract in a curative setting. World J Urol 2013; 31: 109-116
21. Babjuk M, Oosterlinck W, Sylvester R, et al. EAU guidelines on non-muscleinvasive urothelial carcinoma of the bladder, the 2011 update. Eur Urol 2011; 59: 997-1008
22. Lotan Y, Bagrodia A, Passoni N, et al. Prospective evaluation of a molecular marker panel for prediction of recurrence and cancer-specific survival after radical cystectomy. Eur Urol 2013; 64: 465-471
23. Krabbe LM, Bagrodia A, Lotan Y, et al. Prospective analysis of Ki-67 as an independent predictor of oncologic outcomes in patients with high grade upper tract urothelial carcinoma. J Urol 2014; 191: 28-34
24. Yates DR, Roupret M,. Comparing how significantly the pharmacological treatment of genitourinary cancer in a non-curative setting affects endpoints of survival or response. World J Urol 2013; 31: 117-125
25. Colin P, Ghoneim TP, Nison L, et al. Risk stratification of metastatic recurrence in invasive upper urinary tract carcinoma after radical nephroureterectomy without lymphadenectomy. World J Urol 2013. doi: 10.1007/s00345-013-1116-1 [Epub ahead of print]